Literature DB >> 30936032

Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use.

Vadim Yuferov1, Matthew Randesi2, Eduardo R Butelman2, Wim van den Brink3, Peter Blanken4, Jan M van Ree5, Jürg Ott6, Mary Jeanne Kreek2.   

Abstract

The dynorphin/kappa opioid receptor (Dyn/KOR) system is involved in reward processing and dysphoria/anhedonia. Exposure to mu-opioid receptor agonists such as heroin increases expression of the prodynorphin gene (PDYN) in the brain. In this study in a Caucasian cohort, we examined the association of the functional PDYN 68-bp repeat polymorphism with opioid use disorders. In this case-control study, 554 subjects with Caucasian ancestry (142 healthy controls, 153 opioid-exposed, but never opioid dependent, NOD, and 259 with an opioid dependence diagnosis, OD) were examined for association of the PDYN 68-bp repeats with the diagnosis of opioid dependence (DSM-IV criteria), with a dimensional measure of heroin exposure (KMSK scale), and age trajectory parameters of heroin use (age of heroin first use, and age of onset of heaviest use). The PDYN 68-bp repeat genotype (classified as: "short-short" [SS], "long-long" [LL], and "short-long" [SL], based on the number of repeats) was not associated with categorical opioid dependence diagnoses. However, the LL genotype was associated with later age of first heroin use than the SS + SL genotype (19 versus 18 years; p < 0.01). This was also confirmed by a significant positive correlation between the number of repeats and the age of first use of heroin, in volunteers with OD (Spearman r = 0.16; p = 0.01). This suggests that the functional PDYN 68-bp repeat genotype is associated with the age of first use of heroin in Caucasians diagnosed with opioid dependence.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  KMSK; Non-dependent opioid use; Opioid dependence; Prodynorphin polymorphisms; VNTR

Mesh:

Substances:

Year:  2019        PMID: 30936032      PMCID: PMC6594859          DOI: 10.1016/j.neulet.2019.03.038

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  37 in total

1.  Genetic association analyses and meta-analysis of Dynorphin-Kappa Opioid system potential functional variants with heroin dependence.

Authors:  Ji Yuanyuan; Su Rui; Tang Hua; Cui Jingjing; Deji Cuola; Shi Yuhui; Wei Shuguang
Journal:  Neurosci Lett       Date:  2018-08-20       Impact factor: 3.046

2.  Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.

Authors:  Patrick M Beardsley; James L Howard; Keith L Shelton; F Ivy Carroll
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

Review 3.  κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction.

Authors:  Eduardo R Butelman; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Trends Neurosci       Date:  2012-06-16       Impact factor: 13.837

4.  Age at first use and later substance use disorder: Shared genetic and environmental pathways for nicotine, alcohol, and cannabis.

Authors:  Leah S Richmond-Rakerd; Wendy S Slutske; Michael T Lynskey; Arpana Agrawal; Pamela A F Madden; Kathleen K Bucholz; Andrew C Heath; Dixie J Statham; Nicholas G Martin
Journal:  J Abnorm Psychol       Date:  2016-08-18

5.  Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls.

Authors:  Matthew Randesi; Wim van den Brink; Orna Levran; Vadim Yuferov; Peter Blanken; Jan M van Ree; Jurg Ott; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

6.  Association of substance use disorders with childhood trauma but not African genetic heritage in an African American cohort.

Authors:  Francesca Ducci; Alec Roy; Pei-Hong Shen; Qiaoping Yuan; Nicole P Yuan; Colin A Hodgkinson; Lynn R Goldman; David Goldman
Journal:  Am J Psychiatry       Date:  2009-07-15       Impact factor: 18.112

7.  Dissociable effects of kappa-opioid receptor activation on impulsive phenotypes in wistar rats.

Authors:  Brendan M Walker; Jessica L Kissler
Journal:  Neuropsychopharmacology       Date:  2013-05-21       Impact factor: 7.853

8.  Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence.

Authors:  Tanya J Williams; K Steven LaForge; Derek Gordon; Gavin Bart; Scott Kellogg; Jurg Ott; Mary Jeanne Kreek
Journal:  Addict Biol       Date:  2007-06-08       Impact factor: 4.280

9.  Timing of first alcohol use and alcohol dependence: evidence of common genetic influences.

Authors:  Carolyn E Sartor; Michael T Lynskey; Kathleen K Bucholz; Pamela A F Madden; Nicholas G Martin; Andrew C Heath
Journal:  Addiction       Date:  2009-09       Impact factor: 6.526

10.  Methadone Dosage and Plasma Levels, SNPs of OPRM1 Gene and Age of First Drug Use Were Associated With Outcomes of Methadone Maintenance Treatment.

Authors:  Sufang Peng; Haifeng Jiang; Jiang Du; Shuxing Lin; Shujun Pan; Shunying Yu; Min Zhao
Journal:  Front Genet       Date:  2018-10-29       Impact factor: 4.599

View more
  3 in total

1.  Association between prodynorphin gene polymorphisms and opioid dependence susceptibility: a meta-analysis.

Authors:  Chang-Wang Wang; Min Ma; Wei-Guang Lu; Ru-Qin Luo
Journal:  BMC Psychiatry       Date:  2019-09-11       Impact factor: 3.630

Review 2.  Current status of opioid addiction treatment and related preclinical research.

Authors:  M J Kreek; B Reed; E R Butelman
Journal:  Sci Adv       Date:  2019-10-02       Impact factor: 14.136

3.  Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users.

Authors:  Vadim Yuferov; Eduardo R Butelman; Matthew Randesi; Wim van den Brink; Peter Blanken; Jan M van Ree; Mary Jeanne Kreek
Journal:  Neuropsychiatr Dis Treat       Date:  2021-02-25       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.